Intercell Acquires Monoclonal Antibody Assets from Cytos
Debbie Tranter
Abstract
Cytos is to transfer its monoclonal antibody (mAb) technology platform, a specific application of the so-called DELphi™ technology, to Intercell for EUR 15 M.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.